JADE2

Across TCGA pan-cancer cohorts, JADE2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of JADE2’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where JADE2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types JADE2 is over-expressed in tumor, although a few such as PDAC and LUAD show the opposite, repressed pattern.

PDAC, HNSC, and CCRCC are the cancer types where JADE2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in JADE2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Male	All	−0.325	.004	6	view →
HNSC	All	All	+0.271	.004	6	view →
CCRCC	Male	All	+0.128	.001	6	view →
LUAD	Male	III,IV	−0.153	.023	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

JADE2–PDAC

Open the PDAC breakdown →